Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Burchert

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2019
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationRobert Zeiser, Dietrich W Beelen, Wolfgang Bethge, et al.
Hemasphere|May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLJan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
The Lancet. Oncology|September 11, 2012
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialMartin Bornhäuser, Joachim Kienast, Rudolf Trenschel, et al.
American Journal of Hematology|April 13, 2020
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesJuliana Schwaab, Nicole Naumann, Johannes Luebke, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Leukemia|September 11, 2020
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Annals of Hematology|August 17, 2023
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) StudySusanne Isfort, Kirsi Manz, Lino L Teichmann, et al.
Leukemia|May 9, 2020
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2019
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationRobert Zeiser, Dietrich W Beelen, Wolfgang Bethge, et al.
Hemasphere|May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AMLJan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
The Lancet. Oncology|September 11, 2012
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialMartin Bornhäuser, Joachim Kienast, Rudolf Trenschel, et al.
American Journal of Hematology|April 13, 2020
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genesJuliana Schwaab, Nicole Naumann, Johannes Luebke, et al.
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.
Leukemia|September 11, 2020
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Annals of Hematology|August 17, 2023
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) StudySusanne Isfort, Kirsi Manz, Lino L Teichmann, et al.
Leukemia|May 9, 2020
High-risk additional chromosomal abnormalities at low blast counts herald death by CMLRüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Pageof 11